Other · developed by Protagonist Therapeutics
PTG-100 is a drug studied in ulcerative colitis, with daily dosing over a 12-week treatment period.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02895100 | Phase 2 | Ulcerative Colitis | Terminated | PTGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ulcerative Colitis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTGX page.
See PTGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTGX catalysts and pipeline →